Scaffold dependent histone deacetylase (HDAC) inhibitor induced re-equilibration of the subcellular localization and post-translational modification state of class I HDACs

about

Scaffold dependent histone deacetylase (HDAC) inhibitor induced re-equilibration of the subcellular localization and post-translational modification state of class I HDACs

Item

http://www.wikidata.org/entity/Q42680055

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Scaffold dependent histone dea ...... ication state of class I HDACs

@en

Scaffold dependent histone deacetylase

@nl

type

Item

label

Scaffold dependent histone dea ...... ication state of class I HDACs

@en

Scaffold dependent histone deacetylase

@nl

prefLabel

Scaffold dependent histone dea ...... ication state of class I HDACs

@en

Scaffold dependent histone deacetylase

@nl

P1476

Scaffold dependent histone dea ...... ication state of class I HDACs

@en

P2093

Jonna Frasor

http://www.w3.org/2001/XMLSchema#string

Shaimaa M Aboukhatwa

http://www.w3.org/2001/XMLSchema#string

Thomas W Hanigan

http://www.w3.org/2001/XMLSchema#string

P2860

Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation

Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family

Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment.

Cloning and characterization of a novel human histone deacetylase, HDAC8

Histone deacetylases (HDACs): characterization of the classical HDAC family

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

Cloning and characterization of human histone deacetylase 8.

P304

e0186620

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0186620

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Taha Y Taha

Pavel A Petukhov

P577

2017-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29045501

http://www.w3.org/2001/XMLSchema#string

P932

5646865

http://www.w3.org/2001/XMLSchema#string